Supreme Court Justice Samuel Alito temporarily blocked a lower court ruling on Monday that had restricted the mailing of mifepristone, a widely used abortion pill. The U.S. Court of Appeals for the 5th Circuit had reinstated an in-person screening requirement for the drug, prompting drugmakers Danco Laboratories and GenBioPro to seek emergency intervention from the Supreme Court. Alito granted an administrative stay, pausing the 5th Circuit’s decision until 5 p.m. on May 11, while the full court considers the emergency petitions. Louisiana officials, who filed the lawsuit challenging the FDA’s 2023 rule change, were given until 5 p.m. on Thursday to respond.
Part 1: Immediate Action & Core Facts
The Supreme Court’s temporary block allows mifepristone to continue being mailed to patients nationwide, reversing the 5th Circuit’s ruling. The FDA had removed the in-person requirement in 2023, a decision now under legal challenge by Louisiana officials.
Part 2: Deeper Dive & Context
Legal Background
The lawsuit targets the FDA’s 2023 decision to lift the in-person requirement for mifepristone, which was part of broader regulatory changes following the 2022 Dobbs v. Jackson Women’s Health Organization ruling. The 5th Circuit’s decision to reinstate the requirement was seen by drugmakers as creating “nationwide chaos.”
Policy Implications
Mifepristone is used in approximately two-thirds of all abortions in the U.S. The FDA’s rule change aimed to expand access, particularly in states with restrictive abortion laws. The Supreme Court’s intervention ensures continued access while the legal battle unfolds.
Opposing Perspectives
Louisiana officials argue the FDA’s rule change bypassed proper regulatory processes, while drugmakers and abortion rights advocates contend that restricting access undermines medical safety and patient autonomy. The Supreme Court’s decision to pause the 5th Circuit ruling reflects the ongoing legal and political tensions over abortion access.